BACKGROUND: Although long-term steroid treatment is discouraged in ulcerative colitis, alternatives are lacking when therapy with immunosuppressant drugs fails. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis. OBJECTIVE: To see whether steroid withdrawal is easier with retarded-release phosphatidylcholine or placebo in adults with chronic steroid-refractory ulcerative colitis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted from March 2003 to January 2006. SETTING:University Hospital Heidelberg, a referral center for inflammatory bowel disease. PATIENTS: 60 patients with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity indexes (score > or =5). INTERVENTION: Phosphatidylcholine or cellulose placebo was ingested 4 times daily for 12 weeks for a total dosage of 2 g/d. The follow-up rate was 97%. MEASUREMENTS: The number of patients achieving complete steroid withdrawal and either a low clinical activity index (< or =3) or improvement in the clinical activity index of 50% or more. RESULTS: The primary end point was achieved in 15 of 30 (50%) phosphatidylcholine recipients and in 3 of 30 (10%) placebo recipients (difference, 40% [95% CI, 19% to 61%]; P = 0.002). Twenty-four phosphatidylcholine recipients (80%) and 3 (10%) placebo recipients discontinued steroid therapy without disease exacerbation (difference, 70% [CI, 52% to 88%]; P <0.001). Mild bloating was a common adverse event. LIMITATIONS: The sample size was small, and the study was of short duration. CONCLUSION:Phosphatidylcholine reduced corticosteroid dependence more than placebo in patients with chronic steroid-refractory ulcerative colitis. The next step is long-term trials to evaluate the sustainability of steroid withdrawal in these patients. ClinicalTrials.gov registration number: NCT00259545.
RCT Entities:
BACKGROUND: Although long-term steroid treatment is discouraged in ulcerative colitis, alternatives are lacking when therapy with immunosuppressant drugs fails. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis. OBJECTIVE: To see whether steroid withdrawal is easier with retarded-release phosphatidylcholine or placebo in adults with chronic steroid-refractory ulcerative colitis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted from March 2003 to January 2006. SETTING: University Hospital Heidelberg, a referral center for inflammatory bowel disease. PATIENTS: 60 patients with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity indexes (score > or =5). INTERVENTION: Phosphatidylcholine or cellulose placebo was ingested 4 times daily for 12 weeks for a total dosage of 2 g/d. The follow-up rate was 97%. MEASUREMENTS: The number of patients achieving complete steroid withdrawal and either a low clinical activity index (< or =3) or improvement in the clinical activity index of 50% or more. RESULTS: The primary end point was achieved in 15 of 30 (50%) phosphatidylcholine recipients and in 3 of 30 (10%) placebo recipients (difference, 40% [95% CI, 19% to 61%]; P = 0.002). Twenty-four phosphatidylcholine recipients (80%) and 3 (10%) placebo recipients discontinued steroid therapy without disease exacerbation (difference, 70% [CI, 52% to 88%]; P <0.001). Mild bloating was a common adverse event. LIMITATIONS: The sample size was small, and the study was of short duration. CONCLUSION:Phosphatidylcholine reduced corticosteroid dependence more than placebo in patients with chronic steroid-refractory ulcerative colitis. The next step is long-term trials to evaluate the sustainability of steroid withdrawal in these patients. ClinicalTrials.gov registration number: NCT00259545.
Authors: Rauf Onur Ek; Mukadder Serter; Kemal Ergin; Serpil Cecen; Cengiz Unsal; Yuksel Yildiz; Mehmet D Bilgin Journal: Int J Clin Exp Med Date: 2014-04-15
Authors: Daniel Gotthardt; Annika Braun; Anke Tietje; Karl Heinz Weiss; Robert Ehehalt; Wolfgang R Stremmel Journal: World J Gastroenterol Date: 2009-12-14 Impact factor: 5.742
Authors: Annika Braun; Ulrike Schönfeld; Thilo Welsch; Martina Kadmon; Benjamin Funke; Daniel Gotthardt; Alexandra Zahn; Frank Autschbach; Peter Kienle; Michael Zharnikov; Michael Grunze; Wolfgang Stremmel; Robert Ehehalt Journal: Int J Colorectal Dis Date: 2011-04-01 Impact factor: 2.571
Authors: Manu V Chakravarthy; Irfan J Lodhi; Li Yin; Raghu R V Malapaka; H Eric Xu; John Turk; Clay F Semenkovich Journal: Cell Date: 2009-07-30 Impact factor: 41.582
Authors: Alexandra Zahn; Thomas Giese; Max Karner; Annika Braun; Ulf Hinz; Wolfgang Stremmel; Robert Ehehalt Journal: BMC Gastroenterol Date: 2009-02-09 Impact factor: 3.067